Incidence and Prevalence of Neovascular Age-Related Macular Degeneration in France between 2008 and 2018

Garcher, Catherine P. Creuzot; Srour, Mayer; Baudin, Florian; Daïen, Vincent; Dot, Corinne; Nghiem-Buffet, Sylvia; Girmens, Jean-François; Coulombel, Nicolas; Ponthieux, Anne; Delcourt, Cécile

doi:10.1016/j.xops.2022.100114

Cited by 13 publications

(12 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The prevalence of nAMD increases with advancing age from 1% in 70–74 year olds, to 2% in 75–79 year olds and to 3%–6% in 80–84 year olds (Creuzot‐Garcher et al, 2022; Sedeh et al, 2017). Among our glaucoma patients, the cumulative rate of nAMD with anti‐VEGF treatment was 2% with the mean age of 74–75 years (Figure 1).…”

Section: Discussionmentioning

confidence: 99%

Glaucoma progression in patients receiving intravitreal anti‐VEGF treatment for neovascular age‐related macular degeneration

Pirinen

Leinonen

Helminen

et al. 2022

Acta Ophthalmologica

View full text Add to dashboard Cite

The purpose of this study was to investigate how often glaucoma and neovascular age-related macular degeneration (nAMD) occur in the same patient and to evaluate whether glaucoma progression is faster in eyes treated with intravitreal anti-VEGF medications for nAMD. Methods: This single-centre retrospective real-world data (RWD) consists of medical records of 6314 glaucoma and 2166 nAMD patients treated in 2008-2017 in Tays Eye Centre, Finland. To study glaucoma progression, changes in visual fields (mean deviation [MD], dB/year), IOP (mmHg/year) and fundus photographs (progression, yes/no) were compared in glaucoma eyes with and without anti-VEGF treatment for nAMD and ≥1 year follow-up. Results: During the 10-year period, 147 patients with glaucoma received intravitreal anti-VEGF treatment for nAMD corresponding to 2% of glaucoma and 7% of nAMD patients. The mean change in MD was −0.70 dB/year (SD 1.8) vs. −0.27 dB/ year (SD 1.7) (p = 0.027) in glaucoma eyes with (n = 37) and without (n = 4304) anti-VEGF injections, respectively. In patients with bilateral glaucoma and unilateral nAMD treated with anti-VEGF injections (n = 20), MD declined at −0.62 dB/year (SD 1.9) vs 0.33 dB/year (SD 1.5) (p = 0.654), and glaucoma progression was detected in 14/20 vs 10/20 (p = 0.219) fundus photographs in eyes with anti-VEGF treatment compared with their untreated fellow eyes. Conclusion: nAMD and glaucoma were found co-existing in the same eye at rates that were similar to the age-corrected prevalence of the two diseases in the general population. Our results suggest that intravitreal anti-VEGF treatment for nAMD may accelerate glaucoma progression.

show abstract

Section: Discussionmentioning

confidence: 99%

Glaucoma progression in patients receiving intravitreal anti‐VEGF treatment for neovascular age‐related macular degeneration

Pirinen

Leinonen

Helminen

et al. 2022

Acta Ophthalmologica

View full text Add to dashboard Cite

show abstract

“…7 Considering the difference in the incidence and prevalence of nAMD by patient sex, we also performed the multivariable regressions among females and males. 15,16…”

Section: Methodsmentioning

confidence: 99%

“…7 Considering the difference in the incidence and prevalence of nAMD by patient sex, we also performed the multivariable regressions among females and males. 15,16 Statistical significance was set at a = 0.05. Many analyses were performed in this study, so the Type I error rate may have been inflated.…”

Section: Statistical Analysesmentioning

confidence: 99%

Association of metformin use with risk of newly onset neovascular age-related macular degeneration development

Khanna,

Shaw,

Hyman

et al. 2023

Retina

View full text Add to dashboard Cite

Purpose: To investigate if metformin use reduces the odds of developing new neovascular AMD (nAMD). Methods: This is a case-control study of 86,930 subjects with new diagnoses of nAMD and 86,918 matched controls using the Merative™ Marketscan® Research Databases. Subjects were analyzed using multivariable conditional logistic regression to identify the risks of various exposures on developing nAMD. A subgroup analysis of 22,117 diabetic cases and 21,616 diabetic controls was also performed. Results: Metformin use was associated with reduced odds ratio (OR) of developing nAMD (OR 0.95, 95% confidence interval 0.91-0.98) in full sample and diabetic cohort particularly in patients without any diabetic retinopathy (DR) —an effect that persisted after Bonferroni correction. In the diabetic cohort without DR, reduced OR was observed at 24-month cumulative doses of 1 to 300g, 301 to 630g, and 631 to 1080g. Conclusions: Metformin use was associated with reduced OR of nAMD, particularly in patients without DR. The protective effect was noted for 24-month cumulative doses below 1080g. Metformin may be a novel preventive strategy for nAMD.

show abstract

“…AMD is the leading cause of vision loss in people above the age of 50 in developed countries with an estimated prevalence of 288 million worldwide by 2040 [343][344][345][346][347]. Multiple factors are involved in its development and progression including the genetic component, cardiovascular risk factors, and lifestyle.…”

Section: Fundus Autofluorescence In Age-related Macular Degeneration ...mentioning

confidence: 99%

Lipofuscin, Its Origin, Properties, and Contribution to Retinal Fluorescence as a Potential Biomarker of Oxidative Damage to the Retina

Różanowska¹

2023

Preprint

View full text Add to dashboard Cite

Lipofuscin accumulates with age as intracellular fluorescent granules originating from incomplete lysosomal digestion of phagocytosed and autophagocytosed material. The purpose of this review is to provide an update on the current understanding of the role of oxidative stress and/or lysosomal dysfunction in lipofuscin accumulation and its consequences, particularly for retinal pigment epithelium (RPE). Next, the fluorescence of lipofuscin, spectral changes induced by oxidation, and its contribution to retinal fluorescence are discussed. This is followed by reviewing recent developments in fluorescence imaging of the retina, and the current evidence on the prognostic value of retinal fluorescence for the progression of age-related macular degeneration (AMD), the major blinding disease affecting elderly people in developed countries. The evidence of lipofuscin oxidation in vivo, and the evidence of increased oxidative damage in AMD retina ex vivo lead to the conclusion that imaging of spectral characteristics of lipofuscin fluorescence may serve as a useful biomarker of oxidative damage which can be helpful in assessing the efficacy of potential antioxidant therapies in retinal degenerations associated with accumulation of lipofuscin and increased oxidative stress. Finally, amendments to currently used fluorescence imaging instruments are suggested, to be more sensitive and specific for imaging spectral char-acteristics of lipofuscin fluorescence.

show abstract

Incidence and Prevalence of Neovascular Age-Related Macular Degeneration in France between 2008 and 2018

Cited by 13 publications

References 41 publications

Glaucoma progression in patients receiving intravitreal anti‐VEGF treatment for neovascular age‐related macular degeneration

Glaucoma progression in patients receiving intravitreal anti‐VEGF treatment for neovascular age‐related macular degeneration

Association of metformin use with risk of newly onset neovascular age-related macular degeneration development

Lipofuscin, Its Origin, Properties, and Contribution to Retinal Fluorescence as a Potential Biomarker of Oxidative Damage to the Retina

Contact Info

Product

Resources

About